Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
Lilly, Gilead, Amgen started at outperform by Bernstein
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
Business Wire1h
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
FiercePharma1d
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Fintel on MSN1d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform Recommendation
Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...
FiercePharma1d
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Benzinga.com2d
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...
How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
Fintel on MSN11d
Wells Fargo Upgrades Gilead Sciences (GILD)
Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
bovnews5d
The Gilead Sciences, Inc. Rollercoaster: What’s Behind the Latest GILD Stock Fluctuation?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...